|Table of Contents|

Health-related quality of life and influential factors in patients with chronic myeloid leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 22
Page:
4229-4234
Research Field:
Publishing date:

Info

Title:
Health-related quality of life and influential factors in patients with chronic myeloid leukemia
Author(s):
WAN Yuzhu; XU Kaili; LI Wenzhuo; GAO Sujun; LIU Chunshui
Department of Hematology,Cancer Center,the First Hospital of Jilin University,Jilin Changchun 130021,China.
Keywords:
chronic myeloid leukemia; health-related quality of life; influential factors
PACS:
R733.72
DOI:
10.3969/j.issn.1672-4992.2023.22.025
Abstract:
Objective:To evaluate the health-related quality of life (HRQOL) of chronic myeloid leukemia in chronic phase (CML-CP) patients and explore the influential factors.Methods:A total of 83 CML-CP patients treated with tyrosine kinase inhibitor (TKI) were selected from June 2021 to December 2021 in the hematology department of our hospital.The SF-36 scale and the self-made influencing factors scale were used to evaluate the quality of life of the patients.This was a cross-sectional survey.Results:Among 83 CML patients,the median age was 48 years (18~82 years),and 52 cases (62.7%) were male.Univariate analysis showed that different gender,age,education level,income,types of adverse reactions and types of complications had significance differences in quality of life among CML patients (P<0.05).Multivariate analysis indicated that age,education level,type of adverse reactions and complications were independent influencing factors of quality of life in CML patients (P<0.05).Conclusion:The factors affecting quality of life in CML-CP patients include age,education level,adverse effects and complications.In clinical practice,we should pay attention to the prevention and management of adverse effects and complications so as to improve the quality of life of CML patients.

References:

［1］ GOLDMAN JM,MELO JV.Chronic myeloid leukemia-advances in biology and new approaches to treatment ［J］.N Engl J Med,2003,349(15):1451-1464.
［2］ CORTES J,PAVLOVSKY C,SAUBELE S.Chronic myeloid leukaemia ［J］.Lancet,2021,398(10314):1914-1926.
［3］ BOWER H,BJORKHOLM M,DICKMAN PW,et al.Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population ［J］.J Clin Oncol,2016,34(24):2851-2857.
［4］ CORTES JE,SAGLIO G,KANTARJIAN HM,et al.Final 5-year study results of DASISION:The dasatinib versus imatinib study in treatment-Naive chronic myeloid leukemia patients trial ［J］.J Clin Oncol,2016,34(20):2333-2340.
［5］ LARSON RA,HOCHHAUS A,HUGHES TP,et al.Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase:ENESTnd 3-year follow-up ［J］.Leukemia,2012,26(10):2197-2203.
［6］ EFFICACE F,BRECCIA M,SAUSSELE S,et al.Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group ［J］.Ann Hematol,2012,91(9):1371-1381.
［7］ EFFICACE F,GAIDANO G,LO-COCO F.Patient-reported outcomes in hematology:is it time to focus more on them in clinical trials and hematology practice［J］.Blood,2017,130(7):859-866.
［8］ EFFICACE F,CANNELLA L.The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors ［J］.Hematology Am Soc Hematol Educ Program,2016,2016(1):170-179.
［9］ BOSTAN H,TOPTAS T,TANRIKULU FP,et al.Quality of life and symptom burden with first-and second-generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia ［J］.Clin Lymphoma Myeloma Leuk,2020,20(12):836-842.
［10］ EFFICACE F,BACCARANI M,BRECCIA M,et al.Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population ［J］.Blood,2011,118(17):4554-4560.
［11］ EFFICACE F,CASTAGNETTI F,MARTINO B,et al.Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib ［J］.Cancer,2018,124(10):2228-2237.
［12］ EFFICACE F,STAGNO F,IURLO A,et al.Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy ［J］.Leukemia,2020,34(2):488-498.
［13］ FLYNN KE,ATALLAH E.Quality of life and long-term therapy in patients with chronic myeloid leukemia ［J］.Curr Hematol Malig Rep,2016,11(2):80-85.
［14］ HAMERSCHLAK N,DE SOUZA C,CORNACCHIONI AL,et al.Quality of life of chronic myeloid leukemia patients in Brazil:ability to work as a key factor ［J］.Support Care Cancer,2014,22(8):2113-2118.
［15］ MO XD,JIANG Q,XU LP,et al.Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib ［J］.Bone Marrow Transplant,2014,49(4):576-580.
［16］ 中华医学会血液学分会.慢性髓性白血病中国诊断与治疗指南(2020年版) ［J］.中华血液学杂志,2020,41(05):353-364. Society of Hematology,Chinese Medical Association.Chinese Guidelines for Diagnosis and Treatment of Chronic myelogenous leukemia (2020 edition) ［J］.Chinese Journal of Hematology, 2020,41 (05): 353-364.
［17］ MCHORNEY CA,WARE JE,LU JF,et al.The MOS 36-item short-form health survey (SF-36):III.tests of data quality,scaling assumptions,and reliability across diverse patient groups ［J］.Med Care,1994,32(1):40-66.
［18］ EFFICACE F,ROSTI G,AARONSON N,et al.Patient-versus physician-reporting of symptoms and health status in chronic myeloid leukemia ［J］.Haematologica,2014,99(4):788-793.
［19］ JIANG Q,WANG HB,YU L,et al.Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy ［J］.J Cancer Res Clin Oncol,2017,143(6):1013-1022.
［20］ 舒敏,孙薏,王晓冬.慢性髓系白血病慢性期患者健康相关生活质量调查［J］.现代医药卫生,2020,36(02):203-206,210. SHU Min,SUN Yi,WANG Xiaodong.Survey of health-related quality of life in patients with the chronic phase of chronic myeloid leukemia［J］.Modern Medicine and Health,2020,36(02):203-206,210.
［21］ SAUSSELE S,KRAUSS MP,HEHLMANN R,et al.Impact of comorbidities on overall survival in patients with chronic myeloid leukemia:results of the randomized CML study IV ［J］.Blood,2015,126(1):42-49.
［22］ YU L,JIANG Q.Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy ［J］.Chinese Journal of Hematology,2018,39(7):533-539.
［23］ EFFICACE F,ROSTI G,BRECCIA M,et al.The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia ［J］.Ann Hematol,2016,95(2):211-219.
［24］ ZULBARAN-ROJAS A,LIN HK,SHI Q,et al.A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second-and third-generation tyrosine kinase inhibitors ［J］.Cancer Med,2018,7(11):5457-5469.
［25］ EFFICACE F,BACCARANI M,BRECCIA M,et al.Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib ［J］.Leukemia,2013,27(7):1511-1519.
［26］ CELLA D,NOWINSKI CJ,FRANKFURT O.The impact of symptom burden on patient quality of life in chronic myeloid leukemia ［J］.Oncology,2014,87(3):133-147.
［27］ UNNIKRISHNAN R,VEERAIAH S,GANESAN P.Symptom burden and quality of life issues among patients of chronic myeloid leukemia on long-term imatinib therapy ［J］.Indian J Med Paediatr Oncol,2017,38(2):165-168.
［28］ CORTES JE,LIPTON JH,MILLER CB,et al.Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP:The ENRICH Study ［J］.Clin Lymphoma Myeloma Leuk,2016,16(5):286-296.

Memo

Memo:
吉林省科技厅自然科学基金（编号：20190201041JC）
Last Update: 1900-01-01